^
Association details:
| Biomarker: | HER-2 S310Y |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4222: Tucatinib, a selective small molecule HER2 inibitor, is active in HER2 mutant driven tumors
Published date:
05/15/2020
Excerpt:
Tucatinib was tested in 6 HER2 mutant PDX tumor models derived from colorectal, non-small cell lung cancer, gall bladder and gastric cancers with L755S, V77L or S310Y mutations...In two PDX models containing the S310Y extracellular domain mutation of HER2, tucatinib alone, or in combination with trastuzumab, resulted in tumor growth delays.
DOI:
10.1158/1538-7445.AM2020-4222
